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 Abstract 
Despite the fact that ∼85% of bariatric operations are performed in women, the effects of 
the reproductive-axis function on bariatric surgery outcome remain to be determined. 
Here we developed the first published model of Roux-en-Y gastric bypass (RYGB) in 
female rats. We show in ovariectomized rats receiving estradiol or control treatment, that 
(1) RYGB-induced body-weight loss and (2) the satiating efficacy of endogenous 
glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) satiation were significantly 
increased in estradiol-treated rats. These data are relevant to the care of obese women, 
in particular peri-menopausal women undergoing bariatric surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Bariatric surgery is currently the most effective treatment for morbid obesity. 
Morbid obesity (BMI > 40 m/kg2) is more prevalent in women than in men4,8, and the 
adverse effects of obesity on psychological well-being are more pronounced in women5. 
Correspondingly, more than 85% of patients undergoing bariatric surgery are female9. 
Despite the well-known effects of normal reproductive-axis function on eating and body 
weight2, the impact of reproductive-axis function on the outcome of bariatric surgery 
remains to be determined. Here we investigated the effects of Roux-en-Y gastric bypass 
(RYGB) surgery on body weight and glucagon-like peptide-1 (GLP-1)- and 
cholecystokinin (CCK)-induced satiation in a rat model of menopause. 
 
Adult Long-Evans female rats were fattened for 3 wk by offering only a high-
energy diet (Phase 1) before ovariectomy, the standard rodent menopause model, and 
RYGB- or sham surgery. Rats were then fed high-energy and regular chow ad libitum for 
28 d (Phase 2). A near-physiological regimen of estradiol treatment (2 µg estradiol-
benzoate once each 4th d, s.c.), or oil-vehicle treatment (100 µl sesame oil) was begun 
on d 12, resulting in four groups: SHAM-E2, SHAM-OIL, RYGB-E2, and RYGB-OIL. 
Beginning on d 29, rats were fed Ensure Plus liquid diet and chow for 21 d (Phase 3). 
Finally, the acute effects of Exendin (9-39) and Devazepide on Ensure intake were 
tested (Phase 4).  
 
At arrival, rats weighed 185±6 g. During Phase 1, rats gained ∼60 g, reaching an 
overall mean preoperative body weight of 247±3 g (Figure 1A). The continued rapid 
weight gain of SHAM-OIL rats during Phases 2 & 3 was significantly attenuated in 
RYGB-OIL rats (19 vs. 42 g and 30 vs. 67 g in Phases 2 & 3, standard errors of the 
difference, 8 and 7 g, respectively; Figure 1A). The weight-lowering effect of RYGB was 
significantly greater in estradiol-treated rats than oil-treated rats, by 31 and 49 g in 
Phases 2 & 3, respectively. Overall, SHAM-OIL rats gained 109 g during Phases 2 & 3, 
versus 49 g in RYGB-OIL rats and -1 g in RYGB-E2 rats.  
 
RYGB and estradiol treatment had similar effects on energy intake as on body 
weight both during Phase 2, when rats were fed solid, high-energy diet, and during 
Phase 3, when the rats were fed Ensure, which increased energy intake in all groups, 
(Figure 1B). RYGB-OIL rats ate less than SHAM-OIL rats in both Phases, RYGB-E2 rats 
ate less than RYGB-OIL in Phase 2 and tended to eat less in Phase 3 (P < 0.06), and 
SHAM-E2 rats ate less than SHAM-OIL rats in both Phases. RYGB also reduced the 
ratsʼ selection of both test diets vs. chow (Supplementary Table 1). 
 
We tested the effects of Exendin (9-39) and Devazepide, which are potent and 
selective receptor antagonists of GLP-1 and CCK, respectively, during 60-min Ensure 
tests (Phase 4). In both sham-operated and RYGB rats, the antagonistsʼ eating-
stimulatory effects were significantly greater in estradiol-treated than oil-treated rats 
(Figure 2). In neither case, however, was the antagonist effect greater in RYGB-E2 rats 
than in SHAM-E2 rats.  
 
We consider three aspects of our data important. First, to our knowledge, this is 
the first study investigating the influence of reproductive-axis function on bariatric-
surgery outcome. These data are critical because the great majority of gastric bypass 
operations are performed in women and because the reproductive axis, in particular 
estrogens, potently influence the physiology of eating and body-weight control. Second, 
we showed that estradiol significantly increased RYGBʼs potency to reduce weight gain 
and to inhibit eating. Similar effects were obtained when RYGB rats were fed a high-
energy solid diet (Phase 2) and Ensure, a 57%-energy/sugar liquid diet (Phase 3), 
suggesting that they do not depend on particular dietary forms or components. Our data 
suggest that RYGB may be more effective in healthy premenopausal women than in 
postmenopausal women who do not receive hormone-replacement therapy or in women 
with reduced estrogen levels, such as patients with polycystic ovary syndrome7. We are 
not aware of any clinical studies assessing this question, although we found recently that 
bariatric surgery was more effective in postmenopausal-age women than 
premenopausal-age women (Ochner, Geary and Asarian, unpublished). Whether 
estrogens enhance the eating and body-weight lowering effects of RYGB via the same 
mechanisms by which they contribute to the normal control of eating and body weight 
also deserves further research. Furthermore, it is unclear whether estrogens affect the 
outcome of other types of bariatric surgery procedures, such as gastric banding or 
gastric sleeve resection. Third, we provide novel evidence that estrogens increase 
endogenous GLP-1 and CCK satiation in RYGB. In previous reports, estradiol increased 
CCK satiation in rats with intact intestines1,3,6. This is the first report that estradiol also 
increases GLP-1 satiation in intestine-intact rats and that estradiol increases the 
satiating effect of CCK and GLP-1 in RYGB rats. We did not, however, detect any 
difference in the potency of either GLP-1 or CCK in estradiol-treated RYGB vs. estradiol-
treated, sham-operated rats, suggesting that increases in the satiating potencies of 
these peptides alone are not sufficient to account for the decreased total food intake and 
decreased weight gain in our model of RYGB. Possibly larger doses of the antagonists, 
chronic antagonist treatment, or modifications of RYGB method (e.g., longer intestinal 
bypass) would reveal a surgical effect. Finally, other estrogenic effects, such as 
metabolic effects, may also have contributed.  
 
Figure Legends: 
 
Figure 1. Body weights (A) and food intakes (B) following RYGB or sham operation in 
ovariectomized rats that were treated with estradiol (E2) or the oil vehicle (OIL). #SHAM-
OIL vs. RYGB-OIL; *RYGB-OIL vs. RYGB-E2; +SHAM-OIL vs. SHAM-E2; Ps<0.01 for 
body-weight gains and Ps<0.05 for food intakes. 
 
Figure 2. Effects of RYGB on the de-satiating actions of GLP-1 antagonism with Exendin 
(9-39) (A) and of CCK antagonism with Devazepide (B) in ovariectomized rats treated 
with estradiol (E2) or the oil vehicle (OIL). +Estradiol decreased Ensure intake after 
control injections in same surgery group; *Antagonist increased Ensure intake, same 
surgery group; Ps<0.05. 
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